Innate Pharma is a clinical‐stage biotechnology company headquartered in Marseille, France, with additional operations in Paris and Philadelphia. Founded in 1999, the company focuses on the discovery and development of novel immunotherapies that harness the body’s innate immune system to fight cancer. By targeting key receptors on natural killer (NK) cells, macrophages and other innate immune effectors, Innate Pharma seeks to overcome resistance mechanisms and enhance anti‐tumor responses.
The company’s lead investigational candidates include monalizumab, an anti‐NKG2A checkpoint inhibitor being evaluated in combination with established therapies, and lacutamab (IPH4102), a monoclonal antibody directed against KIR3DL2 for the treatment of cutaneous T‐cell lymphomas. Additional pipeline assets such as IPH5201, IPH6401 and IPH6101 are designed to modulate other innate immune checkpoints or to engage immune cells via bi‐ and multi‐specific formats, reflecting Innate Pharma’s broader strategy to develop differentiated antibody‐based therapies.
Innate Pharma has established strategic collaborations with leading pharmaceutical partners, including AstraZeneca and Bristol Myers Squibb, to advance its programs through global clinical development and commercialization. The company’s research and manufacturing operations span Europe and North America, enabling it to conduct multi‐regional clinical trials and to leverage regulatory expertise across key markets.
Leadership at Innate Pharma combines scientific expertise and industry experience. Under the direction of Chief Executive Officer Mondher Mahjoubi and Chief Scientific Officer Philippe Pouletty, the company has grown its immuno‐oncology platform since its inception, bolstered by a board and management team with deep roots in antibody engineering, clinical development and regulatory affairs. Over two decades of innovation have positioned Innate Pharma as a pioneer in innate immunity therapeutics.
AI Generated. May Contain Errors.
Free IPHA Stock Alerts